Acute kidney injury (AKI) is a major clinical problem associated with high morbidity and mortality. Likely due to its complex pathophysiology, therapies with a single pharmacological agent have generally failed to improve outcomes. In contrast, stem cell-based interventions utilize these cells' ability to simultaneously target multiple pathophysiological components of AKI and thus represent a promising new tool for the treatment of AKI. The aims of the this study were to investigate the long-term outcome and safety of treatment with autologous and allogeneic mesenchymal stem cells (MSCs) after AKI and the role of vascular endothelial growth factor (VEGF) as one of the principal paracrine mediators of renoprotection of MSCs. MSC administration after AKI was not associated with adverse events and proved to be renoprotective in animals with severe renal failure. Identical doses of autologous MSC were more effective than allogeneic. At 3 months, MSCs were not engrafted in any tissues except in the bone marrow in 50% of animals given the highest allogeneic cell dose. There was no long-term fi brotic response in the kidneys attributable to MSC therapy, and animals with severe AKI were protected from development of fi brotic lesions after AKI. Furthermore, this study establishes VEGF as a critical factor mediating renal recovery. VEGF knockdown by small-interfering RNA reduced effectiveness of MSCs signifi cantly and decreased survival. In summary, our results show that both autologous and allogeneic MSC are safe and effective in AKI, and importantly, reduce late renal fi brosis and loss of renal function in surviving animals and that VEGF is a critical factor in renoprotection by MSCs. Together, we posit that these data provide further justifi cation for the conduct of clinical trails in which AKI is treated with MSC.
Introduction
T he treatment of acute kidney injury (AKI) has remained a daunting task. Its incidence is on the rise and it is increasingly recognized as a signifi cant cause of endstage renal disease [1] . Due to AKI's complex pathophysiology, it would be expected that therapies with the ability to simultaneously target multiple components of its pathophysiology should afford the highest degree of protection. Adult, bone marrow-derived stem cells (BMDSCs) were found to be very effective in the treatment of organ injuries in animal studies [2] . Importantly, BMDSCs have already found their way into the clinic and proven to be safe and effective in the treatment of humans with various disorders [2] .
Despite intensive research, the mechanisms of action of cell therapy in the various models of AKI remain to be defi ned. Although replacement of damaged parenchymal cells by differentiated hematopoietic stem cells and multipotent marrow stromal or mesenchymal stem cells (MSCs) has been shown to occur in principle, this process takes considerable time and occurs only under rare circumstances thereby making this a subordinate mechanism whereby organ repair is carried out. We and others have shown that administered MSC secrete a number of factors that are known to be renoprotective, thereby making paracrine or endocrine mechanisms the most likely modus operandi whereby administered cells exert their organ protective and repair stimulating effects [3] [4] [5] . MSC are currently the cell type with the highest potential for cell-based therapies because they can be rapidly generated from bone marrow, both in an autologous and allogeneic setting, because largescale culture expansion can be achieved easily, and because they secrete a large number of growth factors and have immunomodulatory properties [6] . MSCs have been shown to be renoprotective in cisplatin-and ischemia/reperfusioninduced AKI [7] [8] [9] in a glomerulonephritis model [10] and are potentially useful in other renal diseases like Alport's syndrome [11] [12] [13] .
Vascular endothelial growth factor (VEGF) is not only a growth and survival factor primarily acting on endothelial cells, but is also involved in matrix remodeling, monocyte chemotaxis, and adhesion molecule expression [14] . VEGF has been shown to be a critical factor for glomerular function and stimulates proliferation of peritubular capillaries, which is essential to tubular regeneration [14] . Furthermore, VEGF directly protects renal epithelial cells [15, 16] . MSCs secrete considerable quantities of VEGF and have vasculoprotective properties [4, 17] . For these reason we hypothesized that VEGF is a major mediator of renoprotection exerted by MSCs. Molecular techniques such as small-interfering RNA (siRNA) allow the specifi c knockdown of a molecule in a cell population and are thereby ideal tools to test this hypothesis.
Because there are insuffi cient dose response and longterm outcomes data from animals whose AKI was treated with MSC, this study was designed to assess the effectiveness of different doses of autologous and allogeneic MSC, as well as the long-term outcomes of animals with ischemia/ reperfusion AKI. Besides monitoring of physiological variables, animals were screened for the development of renal fi brosis or other potential serious side effects such as ectopic differentiation of MSCs or tumor formation. Treatment with both autologous and allogeneic MSC was found to be safe and effective in the short term and did not lead to increased renal fi brosis 3 months after AKI, and reducing VEGF secretion by siRNA knockdown reduced their effectiveness signifi cantly. Furthermore, MSC therapy ameliorated the development of fi brotic reactions and chronic infl ammation in the kidneys in animals with severe initial AKI. We conclude that VEGF is an important mediator of renoprotection by MSCs, and our results further justify the timely conduct of clinical trials in which patients at high risk for or with established AKI are treated with MSC.
Materials and Methods

Animals and cells
All procedures involving animals were approved by the Institutional Animal Use and Care Committees of the University of Utah and Veterans Affairs Medical Center. Heat-resistant human placental alkaline phosphatase (hPAP) transgenic rats were kindly provided by Dr. Eric Sandgren's laboratory [18] .
MSCs for all experiments were generated by standard procedures. In brief, femurs of sacrifi ced rats were fl ushed with saline, and bone marrow cells were collected in tubes, washed, and placed in plastic Falcon tissue culture fl asks (BD Biosciences, San Jose, CA). After 3 days of culture, nonadherent cells were removed and attached MSCs expanded in DMEM/F12 (Sigma) and 10% fetal bovine serum (FBS) (Hyclone, Logan, UT).
For series 1 experiments, MSCs derived from a transgenic hPAP rat were transfected with a G418 resistance gene after expansion over more than 30 passages and selected for transfected cells by G418-medium. MSCs were phenotypically unchanged but had lost their ability to differentiate into mesenchymal lineages (fat-cartilage-bone), most likely due to prolonged culture [19] .
For series 2 and 3 experiments, MSCs were derived from a newborn hPAP positive animal, using standard procedures [7] , and expanded in culture with DMEM/F12 (Sigma) and 10% FBS (Hyclone, Logan, UT) until suffi cient cells for administration were generated. Before administration, batches were tested for mesenchymal differentiation capability and were only used when MSC ISCT criteria were fulfi lled [20] . For all experiments, groups (n = 6 per group) of adult male Sprague-Dawley (SD) or Fisher 344 (F344) rats, weighting 200-300 g, were used (Charles River, Wilmington, MA).
MSC characterization
MSCs were generated from hPAP transgenic F344 rats according to standard procedures. Culture expanded MSCs were negative for CD45 and positive for CD59 and CD90 expression, determined by FACS analysis (data not shown). At the time of administration (approximately 30 passages), MSC for series 2 and 3 experiments readily differentiated into adipocytes, chondrocytes, and osteocytes, and exhibited the characteristic panel of MSC surface markers, confi rming the ISCT criteria for MSCs [20, 21] . MSCs from series 1 experiments were transfected with a G418 resistance plasmid using the Ca-Pho method for selection and tracking, and a resistant clone was selected and expanded. These MSCs were phenotypically unchanged in vitro but failed to differentiate into adipocytes, chondrocytes, and osteocytes, most likely due to prolonged culture and selection [19] .
Surgical procedures and MSC treatment
Ischemia/reperfusion AKI was induced as described before [8] . Three series of experiments were performed containing six animals per group: Series 1 late passage experiments (Allo1) were carried out to determine the renoprotective potential of allogeneic MSCs after severe AKI. Accordingly, renal pedicles of SD rats were clamped for 58 min, and animals were infused immediately after refl ow via the left carotid artery with 1.5 × 10 6 hPAP F344 G418 MSCs in 1 mL of phosphate-buffered saline (PBS). All controls with identical AKI were infused, via the left carotid artery, with an identical volume of PBS. Series 2 experiments (Allo2) were conducted to determine if there exists a dose-response relationship between the number of administered MSCs and the degree of renoprotection that is obtained. Therefore, a low (0.5 × 10 6 per kg bodyweight (BW)), medium (2 × 10 6 per kg BW), and high dose (5 × 10 6 per kg BW) of F344-derived hPAP MSCs was administered once to SD rats via the left carotid artery after 40 min of bilateral renal pedicle clamping and confi rmed refl ow. Finally, to determine the effectiveness of MSCs in the autologous setting, series 3 experiments (Auto1) were conducted. Accordingly, a low (0.5 × 10 6 per kg BW), medium (2 × 10 6 per kg BW), and high dose (5 × 10 6 per kg BW) of F344-derived hPAP MSCs was administered once to syngeneic F344 rats following 35 min of renal clamping and confi rmed refl ow.
Sham operated animals (n = 3) were treated exactly as controls but renal pedicles were not clamped.
Screening for side effects
At the time of sacrifi ce, major organs of animals were macroscopically inspected for tumor formation or ectopic differentiation. Tissue sections were prepared for histology and examined by a pathologist in a blinded fashion.
Kidney function
Serum creatinine, BUN, and urinary protein excretion were determined using the Dimension RxL Max Clinical Chemistry System (Dade Behring, Deerfi eld, IL). Proteinuria and creatinine clearances were determined in 24-h urines collected in metabolic cages. Urine osmolarity was measured by changes in freezing point thermodynamics, using The Advanced™ Osmometer Model 3D3 (Advanced Instruments, Norwood, MA). Blood pressure was determined by tail cuff plethysmography after the animal had been properly accustomed to the utilized procedure.
PCR
All primers were ordered from the University of Utah nucleotide core facility. Tracking of administered cells was performed in tissues by polymerase chain rection (PCR) for the hPAP transgene using primer sequences for the SVpoly40 promoter [18] :
SVpoly-1f: 5′-CTGATGAATGGGAGCAGTGGTGGAATG-3′ and SVpoly-2r: 5′-GCAGACACTCTATGCCCTGTGTGGAG-3′, producing a 360-bp product in transgenic cells.
RT-PCR for fi brotic genes
Real-time PCR with relative quantifi cation of target gene copy numbers in relation to beta-actin transcripts was carried out using the following primers: tumor growth factor-β (TGF-β): 5′-GGACTACTACGCCAAAGAAG-3′ and 5′-TCAAAAGACAGCCACTCAGG-3′; plasminogen activator inhibito-1 (PAI)-1: 5′-GAGCCAGATTCATCATCAACG-3′ and 5′-CTGCAATGAACATGCTGAGG-3′
Histology
Kidneys were histologically evaluated at 3 months after AKI for Allo1, Allo2, and Auto1 groups. Kidney coronary sections were paraffi ne embedded and 4 μm sections were stained with trichrome and PAS, according to standard protocols. Fibrosis scoring in kidneys was performed by a blinded pathologist, using a scoring system of 1-5, with the following criteria: 0-normal; 1-mild tubular atrophy/interstitial fi brosis; 3-moderate tubular atrophy/interstitial fi brosis; 5-marked tubular atrophy/interstitial fi brosis.
VEGF siRNA knockdown
Cultured MSCs were treated with siRNA targeted at three different exons of the VEGF gene, common to all splice variants (exons 2-6) and NeoFx transfection agent (Ambion, Austin, TX). Silencer ® predesigned siRNAs were purchased (Ambion, Austin, TX) and tested at three different concentrations (5, 10, 30 nM) in standard culture medium. Cells were incubated for 24 h with siRNA and washed with PBS. A concentration of 10 nM proved to be most effective and was therefore used for all subsequent experiments. Morphology, viability, and growth rate were not different between VEGF siRNA treated and control MSC preparations. Controls consisted of cells treated with Silencer ® negative control siRNA (Ambion, Austin, TX), NeoFx transfection agent only, and untreated cells. Gene expression of VEGF was assessed 24 and 48 h after knockdown by quantitative reverse transcriptase (RT)-PCR with a SmartCycler (Cepheid, Sunnyvale, CA) and VEGF protein secretion measured by enzyme-linked immunosorbent assay (ELISA) (RnD Systems, Minneapolis, MN) in medium conditioned for 24 h. Injection experiments with VEGF knockdown MSCs and wild-type MSCs after AKI (n = 6 per group) were carried out as described above. Animals were followed for 4 weeks and sacrifi ced thereafter.
Statistical analyses
Data are presented as means ± SD, unless otherwise stated. Statistical analyses were performed using GraphPad Prism 4 for Macintosh (GraphPad Software, San Diego, CA). Analysis of variance and t-tests were used to assess differences between data means as appropriate. A P value of <0.05 was considered signifi cant.
Results
Allogeneic MSCs after AKI
In the Allo1 series, the effectiveness of allogeneic MSCs in AKI was determined. 1.5 × 10 6 hPAP G418 resistant MSCs (corresponding to ~5.5 × 10 6 MSCs per kg BW) were infused into the suprarenal aorta of rats with ischemia/reperfusion AKI. The mortality in the MSC treatment group was lower but did not reach statistical signifi cance using Kaplan-Meier analysis (P = 0.369) ( Fig. 1A ). Renal function, as determined by serum creatinine levels, recovered faster in MSC-treated animals starting at day 2 and became signifi cant at day 3 (P = 0.028) (Fig. 1B) .
The overall aim of this series was to assess the long-term effects of MSC therapy in rats with AKI compared to controls. Accordingly, animals were maintained on standard living conditions for 3 months after induction of AKI, and glomerular fi ltration rate (GFR), thirsting urinary concentration ability, blood pressure, body weight and hematocrits were determined. Surviving, vehicle-treated control animals showed a signifi cant decline in creatinine clearance 3 months after AKI (P = 0.026, Fig. 1C ) compared to baseline, whereas MSC-treated animals had preserved renal function with a slight increase in GFR. Urinary concentrating ability, determined by urine osmolarity, after 24 h of thirsting was not different between groups (Fig. 1D ), as was blood pressure (Fig. 1E ). Hematocrit was higher in MSC-treated animals but did not reach statistical signifi cance (P = 0.054, Fig. 1F ). To determine the extent of renal fi brosis, trichromestained kidney sections were evaluated in blinded fashion by a pathologist. Control animals had more trichrome positive collagenous connective tissue in the renal interstitium animal had a positive signal for the transgene hPAP in heart, lung, liver, spleen, kidney, or bone marrow as determined by RT-PCR (data not shown), suggesting that there was no longterm engraftment of administered MSCs. Testing a panel of fi brosis-related genes [TGF-β, PAI-1, tissue inhibitor of matrix metalloprotease-1 (TIMP-1), Fibronectin, connective tissue growth factor, α-smooth muscle actin], real-time quantitative PCR from renal cortical tissue showed a signifi cant upregulation of TGF-β and TIMP-1 in control animals compared with a sham group (Fig. 4, left panel) . Both genes were signifi cantly downregulated in MSC-treated groups with no signifi cant differences between dosing groups (Fig. 4, right panels) .
Histological scores of kidneys correlated with these data, showing a lower fi bosis score in MSC-treated animals compared with control groups (1.3 vs. 1.5). Although all control animals showed chronic interstitial infl ammation, MSCtreated animals only had mild tubular atrophy and interstitial fi brosis without infl ammatory reaction.
Autologous dose-response study after AKI
To determine the effectiveness and a potential dose response effect of MSC in the autologous setting, a study with hPAP MSC in syngeneic F344 rats was undertaken with the same ischemia/reperfusion model (Auto1). MSC-treated animals were signifi cantly renoprotected in the medium-and as well as greater interstitial infl ammatory cell accumulation ( Fig. 2A, left panel) , refl ected by the respective fi brosis score (2.25 vs. 1.83, Fig. 2B ) and the higher renal expression of profi brotic genes PAI-1 and TGF-β, respectively (P < 0.05, Fig. 2C ).
We showed previously that administered MSC, can only be detected for approximately up to 72 h after infusion. We utilized, therefore, the transgenic marker hPAP to detect infused cells in major organs by a highly sensitive RT-PCR assay. At 3 months, brain, liver, lung, spleen, and kidneys were negative for hPAP, whereas three of six animals had a positive hPAP signal in the bone marrow, indicating that some infused cells had engrafted at this site.
Allogeneic MSC dose-response study after AKI
To further defi ne the relationship between the number of administered MSCs and recovery from renal failure, we undertook a dose-response study using the same rat model. MSC in this series (Allo2) were expanded for ~30 passages and not transfected with the G418 resistance plasmid. There was no statistically signifi cant renoprotection of MSC-treated animals at any administered dose although there was a trend toward better renal function in low-and medium-dose groups (Fig. 3A) . Creatinine clearance at 3 months was not different between groups (Fig. 3B) , as were hematocrit, thirsting osmolarity, proteinuria, and blood pressure (data not shown). No high-dose groups (2 × 10 6 and 5 × 10 6 MSC per kg BW, respectively) but not in the low-dose group (Fig. 5A ). Creatinine clearance at 3 months after AKI was signifi cantly better only in the high-dose MSC treatment group (Fig. 5B ). There were no differences in hematocrit, blood pressure, thirsting urinary osmolarity, and proteinuria between groups. One animal had a positive signal for hPAP in bone marrow and one in the heart, whereas all other animals had no positive PCR signals in heart, lung, liver, spleen, kidney, or bone marrow, suggesting the absence of long-term engraftment of administered MSCs (data not shown).
There was no difference in gene expression for fi brotic genes and fi brosis scores, which is most likely a refl ection of the milder renal injury that was induced in this group.
VEGF knockdown in MSCs reduces renoprotective activity
To determine if VEGF is a signifi cant mediator of renoprotection after AKI, we tested wild-type MSCs and MSCs in which VEGF expression had been knocked down using a siRNA approach. Treatment with three different siRNAs at a concentration of 10 nM targeted against VEGF exons 2-6 resulted in absolute gene downregulation [2-log] of VEGF messenger RNA (mRNA) by −1 to −3, as determined by quantitative real-time RT-PCR and REST-analysis (Fig. 6A ). mRNA downregulation resulted in a signifi cant decrease in VEGF secretion measured by ELISA (Fig. 6B) . When compared to animals treated with unmodifi ed MSCs, animals with AKI that were treated with VEGF knockdown MSC had higher mortality rates and reduced functional recovery ( Fig. 6C and D) .
Discussion
This study was designed to identify possible adverse effects of MSC treatment after AKI over a 3 months period, the human equivalent of 3-4 years of follow-up, to defi ne the effectiveness and dose-dependency of MSC treatment of AKI and to test the hypothesis that VEGF is involved in renoprotection. We show that both autologous and allogeneic MSCs are effective in the immediate treatment for AKI, and furthermore, that there are no signifi cant, MSC-induced adverse effects late after AKI, especially no increase in interstitial renal fi brosis and loss of function. VEGF is identifi ed as mediator of survival and renoprotection by MSCs, because its knockdown increased mortality and led to a delayed recovery of renal function. MSC are able to protect from chronic renal damage, which may be related to the severity of the initial lesion, because it was only observed in rats with severe AKI. Whether this long-term protection is the direct result of MSCs' actions per se or due to the organ protection and enhanced recovery elicited by MSC in the period immediately after injury, cannot be determined directly from our data.
We show here for the fi rst time in an in vivo setting that VEGF is an important mediator of the renoprotective effects of MSCs. Effective knockdown of VEGF by siRNA in administered MSCs increased mortality and led to delayed recovery of renal function. The reason that renal function at day 3 after injury seems not different between MSC and VEGF-knockdown MSC-treated animals is due to the mortality bias in the latter, because animals with most severe renal failure died and so their renal function could not be included into the analysis in Fig. 6C . VEGF is an important trophic factor for the kidney, and mediates a number of different responses such as cellular survival, vasodilation, angiogenesis, matrix remodeling, monocyte chemotaxis, and expression of adhesion molecules [14] . Intriguingly, renal VEGF expression is diminished in vivo after ischemia/ reperfusion injury [22] , and treatment with VEGF in the immediate period after ischemic injury ameliorates resulting damage [23] . Thereby, MSC-delivered VEGF appears to 
MSC
The origin of fi brotic cells in the kidney in this setting is still debated [27, 28, 36, 37] . Possible cellular candidates that have been suggested to contribute to the fi brotic process include tubular epithelial cells via epithelial-mesenchymal transition, renal fi broblasts, renal perivascular smooth muscle cells and extra-renal cell sources. In our hands, administration of exogenous MSCs of either autologous or allogeneic origin does not increase renal fi brosis and appears to have long-term benefi ts. This might be because of the transient nature of engraftment of administered MSCs. MSCs are only found in the kidney for a short-time window after administration, disappearing after 1-3 days. Although this window is suffi cient to elicit a protective response in animal models, MSCs do not per se contribute to subsequent renal remodeling. Improved long-term outcome of treated animals seems to be primarily a function of the early protective effect rather than the presence of MSCs in the long term.
It is currently unknown which MSC population is the best for the treatment of AKI. Duffi eld et al. reported a protective response following MSC administration in ischemic AKI only when MSC were cultured on matrigel, and not when cultured on plastic [38] . The outcome in terms of renoprotection was also different between our series of experiments, showing that autologous MSC were more potent than allogeneic MSC. This could be attributed to differences in culture conditions, passage number (resulting in selection of dominant MSC clones or aging [19, 39, 40] ), or other currently unknown factors. MSCs are a heterogeneous population of cells and there are marked species and strain differences [41] [42] [43] , which might also be determinants contributing to different outcomes.
In summary, we have shown that MSC are safe and effective in the treatment of experimental ischemia/reperfusion AKI in rats, and that VEGF plays a major role mediating their renoprotection. MSC treatment does not result in late adverse effects such as increased renal fi brosis, loss of function, hypertension, ectopic differentiation, or tumor formation. These results further justify, in our opinion, the timely conduct of clinical trails in which patients at high risk for or with established AKI are treated with MSC. We have initiated a Phase I clinical trial in which MSC therapy of AKI is investigated.
improve both short-and long-term function, including late decrease in renal function and fi brosis. Although VEGF is an important factor, as demonstrated by our data, it is likely not the only factor involved in renoprotection as was recently demonstrated by Imberti et al. [24] ). Together, we posit that it is the ability of MSCs to target, through a complex set of mechanisms, several pathophysiological components of AKI, which appears to make cell therapy superior to singleagent pharmacological interventions.
There is concern that MSC administration might lead to or increase interstitial, renal fi brosis, because MSCs are mesodermal, fi broblast-like cells, and TGF-β, which is increased after renal damage and AKI, can promote proliferation and myofi broblast differentiation of MSC [25] [26] [27] [28] . Kunter et al. have shown that the infusion of MSCs into the renal artery of rats with anti-Thy-1 glomerulonephritis ameliorates chronic renal injury (10), while they also observed that high numbers (up to 20%) of glomeruli contained MSCs differentiated into fat cells, potentially obstructing affected nephrons that was associated with periglomerular fi brotic response [29] . When MSCs are infused into the suprarenal aorta, as was done in all studies, no adipogenic differentiation of MSCs is observed, in part due to the fact that cells remain no longer than 3 days in the kidney. Endogenous bone marrow-derived cells have also been shown to contribute to interstitial fi brosis after AKI [25] . Finally, late-passage MSCs have been shown to support tumor growth in animal models [30] .
It has been reported that MSC can reduce organ fi brosis in various injury models, e.g., in lung and liver fi brosis as well as in Alport's syndrome [11, [31] [32] [33] [34] . There are significant differences between endogenous bone marrow cells and exogenously administered cells regarding their respective contribution to organ fi brosis. Although endogenous bone marrow derived cells have been shown to contribute to renal fi brosis [25] , this has not been documented for exogenously administered MSC. MSCs also have immunomodulatory, mainly antiinfl ammatory properties, and infl ammatory conditions are linked to fi brosis [28, 35, 36] . It seems therefore plausible that MSCs might be protective against the development of fi brosis by means of their robust antiinfl ammatory actions. We show here that exogenously administered MSCs do not increase renal fi brosis at 3 months after AKI but rather decreased renal fi brotic reactions in two of the three series of experiments. Protection was obtained with MSC therapy in animals that would develop marked fi brotic responses because of the higher initial severity of the AKI, and profi brotic genes TGF-β and TIMP-1 in these kidneys were expressed at signifi cantly lower levels. Interestingly, only TGF-β and TIMP-1 were elevated in the dose-response series (Allo2) and only PAI-1 in the fi rst allogeneic series (Allo1). The reason for this is unclear. MSC administration immediately after AKI prevented this late upregulation and led to a better outcome at the tissue level. Functional variables such as blood pressures and urinary concentration ability were not different between MSC-and vehicle-treated groups. The lack of differences in blood pressure might be partly explained by the fact that we did not sodium-challenge the animals, a maneuver that is required to induce hypertension after AKI. In addition, residual renal function was obviously adequate to allow for maintained urinary concentration capacity despite histological evidence for tissue injury/fi brosis.
